Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD8αH&TM-41BBζ CAR-T cells
- Development stage
- Preclinical
- Lead developer
- University of Lausanne
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD8αH&TM-41BBζ CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target CD70, a protein frequently expressed in acute myeloid leukemia (AML) and other malignancies. This specific construct utilizes the natural ligand CD27 as the antigen-binding domain, fused to a CD8α hinge and transmembrane domain, a 4-1BB (CD137) costimulatory domain, and a CD3ζ signaling endodomain. Developed by researchers at the University of Lausanne and CHUV, this CAR-T variant was evaluated alongside other CD27-based designs to optimize anti-leukemic potency and circumvent the natural cleavage of CD27. In preclinical studies, while this construct showed activity, it was compared against a redesigned CD8αH-CD27ζ CAR which demonstrated superior efficacy in sequential killing assays and in vivo mouse models.
- Other names
- CD70-targeting CAR-T cells (CD8αH&TM-41BBζ)CD27-41BBζ CAR-T cells
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on CD8αH&TM-41BBζ CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD8αH&TM-41BBζ CAR-T cells.